galeterone

Phase 2Small molecule

LLTN PHARMACEUTICALS, INC.

galeterone is one of 4 small molecule programs targeting Advanced Pancreatic Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Pancreatic CancerActive, not recruiting

Advanced Pancreatic CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Advanced Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

2 2

galeterone

LLTN PHARMACEUTICALS, INC.

Phase 2

1 3

IBI343

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

1 4

Nab-Paclitaxel and Gemcitabine

PPrECOG, LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced Pancreatic Cancer

NCT04098081

Clinical

Trials by Indication[1]

Metastatic1 trial

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

Terminated·LLTN PHARMACEUTICALS, INC.·Phase 3·NCT02438007·953 enrolled

Prostate Cancer1 trial

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Terminated·LLTN PHARMACEUTICALS, INC.·Phase 2·NCT01709734·126 enrolled

Absorption1 trial

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

Completed·LLTN PHARMACEUTICALS, INC.·Phase 1·NCT02729376·6 enrolled

Advanced Pancreatic Cancer1 trial

1911GCCC: Open Label, Phase 2 Trial of Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT04098081·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for galeterone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — galeterone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for galeterone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LTN PHARMACEUTICALS, INC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLTN PHARMACEUTICALS, INC.

galeterone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Metastatic1 trial

Prostate Cancer1 trial

Absorption1 trial

Advanced Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News